SIRT3 and familial dilated cardiomyopathy: Future study should prioritize: (1) developing SIRT3‐specific small‐molecule agonists; (2) elucidating the role of SIRT3 subtypes in disease progression; (3) clinical validation of SIRT3 as a biomarker for DCM; (4) investigation of combination therapy using SIRT3 activators alongside conventional antidiabetic drugs.